文献速递真菌感染艾滋病与性传播感染

抗GM-CSF自身抗体可预测未感染HIV的隐球菌脑膜炎患者的结局:一项队列研究

Anti-GM-CSF autoantibodies predict outcome of cryptococcal meningitis in patients not infected with HIV: A cohort study.
PubMed 文献 · Clin Microbiol Infect · 2024-01-29

该回顾性队列纳入584例非HIV隐球菌脑膜炎患者,455例检测血清抗GM-CSF自身抗体,37例(8.1%)阳性。抗体阳性者更易感染格特隐球菌复合种(66.7% vs 6.3%,p<0.001)及出现直径>3厘米的肺部肿块(42.9% vs 6.5%,p=0.001)。单变量Cox回归显示抗体与1年生存率降低相关(HR 2.66,95%CI 1.34-5.27,p=0.005)。

要点

  • 非HIV隐球菌脑膜炎患者中血清抗GM-CSF自身抗体阳性率为8.1%(37/455)。
  • 抗体阳性者更易感染格特隐球菌复合种及出现>3厘米肺部肿块。
  • 抗GM-CSF自身抗体与1年生存率降低相关(HR 2.66,95%CI 1.34-5.27)。

核心结论

  • 血清抗GM-CSF自身抗体的存在可预测不良结局,无论宿主免疫状态和致病隐球菌复合种如何。

研究设计与样本

  • 回顾性研究,纳入12年间非HIV隐球菌脑膜炎病例共584例。
  • 检测血清抗GM-CSF自身抗体,评估临床特征和结局,并探索2周和1年生存的预后因素。

主要发现

  • 584例中301例(51.5%)表型健康。
  • 264株脑脊液培养隐球菌中,251株为新型隐球菌复合种,13株为格特隐球菌复合种。
  • 455例检测血清抗GM-CSF自身抗体,37例(8.1%)阳性。
  • 抗体阳性者更易感染格特隐球菌复合种(66.7% vs 6.3%,p<0.001),更易出现直径>3厘米的肺部肿块(42.9% vs 6.5%,p=0.001)。
  • 584例中16例(2.7%)在2周内死亡,563例中77例(13.7%)在1年时死亡,486例中93例(19.1%)在1年时残疾生存。

关键数值与推荐

  • 单变量Cox回归:抗GM-CSF自身抗体与1年生存率降低相关(HR 2.66,95%CI 1.34-5.27,p=0.005)。
  • 多变量Cox比例风险模型:脑脊液隐球菌抗原滴度≥1:1280与2周生存率降低(HR 5.44,95%CI 1.23-24.10,p=0.026)和1年生存率降低(HR 5.09,95%CI 1.95-13.26,p=0.001)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the seroprevalence of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies in non-HIV cryptococcal meningitis (CM) and assess its predictive value for survival. METHODS: This is a retrospective study of 12 years of non-HIV CM. We detected serum anti-GM-CSF autoantibodies, and evaluated the clinical features and outcomes, together with the exploration of prognostic factors for 2-week and 1-year survival. RESULTS: A total of 584 non-HIV CM cases were included. 301 of 584 patients (51.5%) were phenotypically healthy. 264 Cryptococcus isolates were obtained from cerebrospinal fluid (CSF) culture, of which 251 were identified as C. neoformans species complex and 13 as C. gattii species complex. Thirty-seven of 455 patients (8.1%) tested positive for serum anti-GM-CSF autoantibodies. Patients with anti-GM-CSF autoantibodies were more susceptible to C. gattii species complex infection (66.7% vs. 6.3%; p < 0.001) and more likely to develop pulmonary mass lesions with a diameter >3 centimetres (42.9% vs. 6.5%; p 0.001). Of 584 patients 16 (2.7%) died within 2 weeks, 77 of 563 patients (13.7%) died at 1 year, and 93 of 486 patients (19.1%) lived with disabilities at 1 year. Univariant Cox regression analysis found that anti-GM-CSF autoantibodies were associated with lower 1-year survival (HR, 2.66; 95% CI, 1.34-5.27; p 0.005). Multivariable Cox proportional hazards modelling revealed that CSF cryptococcal antigen titres ≥1:1280 were associated with both, reduced 2-week and 1-year survival rates (HR, 5.44; 95% CI, 1.23-24.10; p 0.026 and HR, 5.09; 95% CI, 1.95-13.26; p 0.001). DISCUSSION: Presence of serum anti-GM-CSF autoantibodies is predictive of poor outcomes, regardless of host immune status and the causative Cryptococcus species complex.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Jiang YK, Zhou LH, Cheng JH, et al. Anti-GM-CSF autoantibodies predict outcome of cryptococcal meningitis in patients not infected with HIV: A cohort study. Clin Microbiol Infect. 2024. PMID: 38295989. doi:10.1016/j.cmi.2024.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。